We discuss results from the Checkmate-274 and IMvigor010 trials on adjuvant immune checkpoint inhibitor (ICI) therapy in muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC), and conclude that adjuvant ICI (nivolumab but not atezolizumab) should be considered for patients with resected high-risk MIBC, especially for those who have received NAC.

中文翻译：

---

肌肉浸润性膀胱癌中的辅助免疫检查点抑制：准备好迎接黄金时段了吗？

我们讨论了 Checkmate-274 和 IMvigor010 试验对肌肉浸润性膀胱癌 (MIBC) 的辅助免疫检查点抑制剂 (ICI) 治疗联合或不联合新辅助化疗 (NAC) 的结果，并得出结论认为辅助 ICI（纳武利尤单抗而非阿特珠单抗）应该考虑用于切除高危 MIBC 的患者，尤其是接受 NAC 的患者。